Entecavir Shortage: What Providers and Prescribers Need to Know in 2026

Entecavir (Baraclude) remains a first-line treatment for chronic hepatitis B virus (HBV) infection per both the 2025 AASLD/IDSA and EASL Hepatitis B guidelines. While no nationwide FDA shortage exists as of 2026, clinicians managing HBV patients increasingly report that patients encounter localized pharmacy stockouts—a problem that carries real clinical risk given entecavir's boxed warning regarding severe hepatitis B exacerbations upon abrupt discontinuation.

This guide is intended for hepatologists, gastroenterologists, infectious disease specialists, and primary care providers who prescribe entecavir, to help them proactively counsel patients, identify alternatives when needed, and navigate the current availability landscape.

Current Availability Status (2026)

As of 2026, entecavir is not listed on the FDA Drug Shortages database. Generic entecavir is manufactured by multiple firms, including Teva, Aurobindo, Cipla, and others. Multiple generics entering the US market following patent expiration has generally stabilized supply and lowered costs (generic prices as low as $11–$31/30-tablet supply with discount cards).

Despite this, individual pharmacies—particularly independent pharmacies, rural locations, and pharmacies that primarily service high-turnover medications—may periodically run out. The oral solution (0.05 mg/mL) is particularly vulnerable to localized stockouts, as demand is low and the product is not routinely stocked by most retail chains.

Clinical Risks of Entecavir Discontinuation

Clinicians must counsel patients not to stop entecavir without medical supervision. The FDA-mandated boxed warning requires:

• Severe acute HBV exacerbations: Documented risk of ALT flares and hepatic decompensation upon stopping anti-HBV therapy, including entecavir. Monitor hepatic function closely for at least several months after any discontinuation.
• HIV resistance risk in unrecognized co-infection: Entecavir carries modest anti-HIV activity and should not be used in HIV/HBV co-infected patients not receiving fully suppressive antiretroviral therapy (ART). Patients should be screened for HIV before initiating entecavir.
• Lactic acidosis: Rare but potentially fatal. Risk increases in patients with hepatic decompensation, female sex, obesity, and prolonged nucleoside analogue use.

Therapeutic Alternatives: When a Switch Is Clinically Warranted

Per the 2025 AASLD/IDSA guidelines, entecavir, TDF, and TAF are co-preferred first-line agents with comparable efficacy (68–90% achieving undetectable HBV DNA at 48 weeks) and high genetic barrier to resistance. If entecavir cannot be obtained, clinicians may consider switching to:

• Tenofovir disoproxil fumarate (TDF, Viread) 300 mg QD: Co-first-line, widely available generic, preferred in pregnancy and HIV co-infection. Monitor renal function and bone density, particularly in patients at elevated risk.
• Tenofovir alafenamide (TAF, Vemlidy) 25 mg QD: Co-first-line, improved renal and bone safety versus TDF, preferred in patients with CKD, osteoporosis, or at risk for bone/renal adverse effects. Still brand-name as of 2026; cost may be a barrier.

Note: Lamivudine is not recommended as a substitute due to its high resistance rates (~70% at 5 years). Pegylated interferon is not an appropriate short-term bridge.

Special Populations: Entecavir Dosing Considerations

Prescribers should be aware of key dosing adjustments:

• Renal impairment: Dose adjustment required for CrCl <50 mL/min, hemodialysis, and CAPD patients. Entecavir is predominantly renally eliminated (62–73% urinary recovery of unchanged drug).
• Hepatic impairment: No dose adjustment needed for Child-Pugh A or B/C hepatic impairment. Decompensated liver disease patients receive 1 mg QD (not 0.5 mg).
• Pediatric patients (≥2 years, ≥10 kg): Weight-based oral solution dosing. The 0.05 mg/mL oral solution may be harder to source—specialty pharmacies are typically best.
• Lamivudine-resistant patients: Require 1 mg QD (not 0.5 mg). The 1 mg tablet may be harder to locate at retail pharmacies than the 0.5 mg—advise patients to check specialty pharmacies.

Patient Counseling Points for Providers

At each visit, consider proactively addressing medication access:

• Remind patients never to stop entecavir without calling your office first
• Prescribe 90-day supplies where insurance allows to reduce refill friction
• Recommend patients use GoodRx or medfinder to find pharmacies that stock entecavir
• Consider directing patients to the Good Days Patient Assistance Program (1-877-968-7233) for financial assistance

How medfinder Can Support Your Patients

medfinder is a service that calls pharmacies on behalf of patients to find which ones have their medication in stock. Providers can recommend medfinder.com/providers to learn how it can integrate into their patient support workflow. See also our dedicated guide: How to Help Your Patients Find Entecavir in Stock.